PubMed Health⌕ Search

PubMed · 9543765

[Current lymphoma classification: a step forward for pathologists and clinicians].

Abstract

Non-Hodgkin lymphomas encompass a heterogeneous group of lymphoid malignancies from the clinical as well as from the pathological point of view. Consequently, one condition of optimal communication among pathologists, clinicians and scientific researchers is an adequate classification system. A new classification of lymphomas was proposed in September 1994, the Revised European-American Lymphoma Classification (REAL classification). The REAL classification is aiming at integration of pathological and clinical data, making it possible to distinguish clinical-pathological entities each of which has its characteristic pathological spectrum, clinical evolution and clinical presentation. The REAL classification is based not only on morphological and immunohistochemical but also on molecular and cytogenetic data. Such a system may make it possible to develop specific therapies for specific pathological entities. The REAL classification constitutes an important step forward in haemato-oncology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D de Jong, P M Kluin. 1997-08-16. [Current lymphoma classification: a step forward for pathologists and clinicians].. https://pubmed.ncbi.nlm.nih.gov/9543765/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗